JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

Pacific Biosciences of California Inc

Fechado

SetorSaúde

1.58 1.94

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.53

Máximo

1.67

Indicadores-chave

By Trading Economics

Rendimento

-2.4M

-40M

Vendas

6.2M

45M

Margem de lucro

-90.427

Funcionários

485

EBITDA

-6M

-38M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+44.23% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-30M

525M

Abertura anterior

-0.36

Fecho anterior

1.58

Sentimento de Notícias

By Acuity

50%

50%

157 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Pacific Biosciences of California Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de abr. de 2026, 23:15 UTC

Notícias Principais

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 de abr. de 2026, 23:08 UTC

Ganhos
Grandes Movimentos do Mercado

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 de abr. de 2026, 23:58 UTC

Ganhos

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 de abr. de 2026, 23:58 UTC

Ganhos

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 de abr. de 2026, 23:56 UTC

Ganhos

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 de abr. de 2026, 23:56 UTC

Ganhos

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 de abr. de 2026, 23:42 UTC

Conversa de Mercado

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 de abr. de 2026, 23:30 UTC

Conversa de Mercado

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 de abr. de 2026, 23:08 UTC

Conversa de Mercado

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 de abr. de 2026, 23:02 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de abr. de 2026, 23:02 UTC

Conversa de Mercado

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 de abr. de 2026, 22:42 UTC

Conversa de Mercado

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 de abr. de 2026, 22:10 UTC

Ganhos

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 de abr. de 2026, 22:09 UTC

Ganhos

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 de abr. de 2026, 21:56 UTC

Ganhos

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 de abr. de 2026, 21:55 UTC

Ganhos

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 de abr. de 2026, 21:55 UTC

Ganhos

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 de abr. de 2026, 21:44 UTC

Ganhos

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 de abr. de 2026, 21:43 UTC

Ganhos

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 de abr. de 2026, 21:41 UTC

Ganhos

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 de abr. de 2026, 21:41 UTC

Ganhos

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Basic Materials Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Financial Services Roundup: Market Talk

27 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Health Care Roundup: Market Talk

27 de abr. de 2026, 20:39 UTC

Ganhos

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Comparação entre Pares

Variação de preço

Pacific Biosciences of California Inc Previsão

Preço-alvo

By TipRanks

44.23% parte superior

Previsão para 12 meses

Média 2.25 USD  44.23%

Máximo 3 USD

Mínimo 1 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Pacific Biosciences of California Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

5 ratings

2

Comprar

2

Manter

1

Vender

Pontuação Técnica

By Trading Central

1.13 / N/ASuporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

157 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat